IngredientsPhanerochaete chrysosporium is a fungus of the phylum Basidiomycetes, of the class Agaricomycetes, of the Polyporales order, and of the Phanerochaetaceae family. Its formal scientific name, as described by Burdsall in 1974, carries a heterotypic synonym: Sporotrichum pruinosum Gilman & Abbott, 1927. In recent phylogenetic reclassifications, the species has also been placed under the name Phanerodontia chrysosporium, though the classical name Phanerochaete chrysosporium remains the most widely used in the scientific literature.
The genus Phanerochaete belongs to a genus of crust fungi in the family Phanerochaetaceae. Basidiomycetes are the second most numerous phylum in the fungi kingdom, after Ascomycetes, and are estimated to contain over 40,000 different species of fungi. Basidiomycetes are mainly characterized by the shape of their spore-producing organs, called basidia, which are reminiscent of a club or club-like shape with spores at the ends.
Phanerochaete chrysosporium is a resupinate, or crust fungus, that decays wood. These fungi are responsible for a good deal of the wood decay in logs lying on the ground in nature; they never form a mushroom for reproduction, but form effused, very flat, fruiting bodies that appear as no more than a crust on the underside of a log.
P. chrysosporium's sustainability at moderate to higher temperatures, specifically 40°C, means this white-rot fungus can be found in forests ranging from North America to areas of Europe and Iran. A main role it assumes is that of degradation of the complex lignin from various trees and plants.
Phanerochaete chrysosporium is not a traditional dietary supplement in the customary sense of orally consumed products, and it has no recognized history of traditional use in human nutrition or ethnomedicine. Its primary documented applications are biotechnological rather than nutraceutical. In research and industrial settings, the organism is prepared and applied in a number of forms:
Phanerochaete chrysosporium has no documented history of traditional use in any known ethnomedicinal, culinary, or folk medicine tradition. It does not appear in standard ethnopharmacological references as a plant, herb, or mushroom consumed by any human culture for health or medicinal purposes. Unlike edible or medicinal mushrooms such as Lentinula edodes (shiitake) or Ganoderma lucidum (reishi), P. chrysosporium is a non-edible, inconspicuous corticioid (crust) fungus that forms flat, undistinguished fruiting bodies and does not produce a recognizable mushroom structure. Its interest in applied science is entirely a product of 20th- and 21st-century industrial microbiology, biotechnology, and environmental science.
The scientific investigation of P. chrysosporium began in earnest in the 1970s and 1980s, when researchers discovered its extraordinary ability to degrade lignin, the aromatic polymer that gives wood its rigidity. The biodegradation of lignin plays an essential part in the terrestrial carbon cycle; after cellulose, this compound represents the most abundant organic material capable of renewing itself. The organism's potential for bioremediation and biotechnological applications has driven all subsequent research interest.
Phanerochaete chrysosporium is considered the model fungus for white rot fungi; its importance lies in the fact that its enzymatic system comprises the major enzymes involved in lignin degradation, a complex and highly recalcitrant compound that very few living organisms are capable of degrading naturally. The ligninolytic enzyme system of P. chrysosporium is recognized as the most complete of all enzyme complexes produced by other ligninolytic fungi, which is one of the main reasons why it is considered the model strain for ligninolytic activity.
P. chrysosporium has a system composed of three main enzymes that work in concert to degrade lignin, phenolics, aromatics, and similar compounds: laccase, lignin peroxidase, and manganese peroxidase, which are oxidoreductases.
Lignin and manganese peroxidases are secreted by P. chrysosporium during secondary metabolism, and these enzymes play major roles in lignin degradation. LiP has a higher redox potential than laccases and MnP; it can oxidize both phenolic and non-phenolic substructures of lignin even in the absence of mediators, and therefore appears to be more effective than laccase. The active site amino acid sequence of these lignin-degrading peroxidases is similar to that of horseradish peroxidase (HRP) and cytochrome c peroxidase (CcP), and the mechanism by which they oxidize substrates also appears to be similar.
Lignin-degrading peroxidases are able to catalyze the oxidation of substrates with high redox potential, an ability consistent with a heme active site of low electron density. These enzymes act nonspecifically via the generation of lignin free radicals, which undergo spontaneous cleavage reactions; lignin peroxidase (LiP) oxidizes phenolic and nonphenolic substrates by one electron, whereas manganese peroxidase (MnP) oxidizes Mn²⁺ to Mn³⁺.
Manganese peroxidases are extracellular glycosylated proteins with molecular masses ranging from 32–62.5 kDa, belonging to the family of oxidoreductases; the first MnP was discovered in Phanerochaete chrysosporium in the mid-1980s. MnP oxidizes Mn(II) to Mn(III), and the latter acts as a freely diffusible one-electron oxidizer, nonspecifically reacting with terminal organic substrates such as phenols, thiols, and lignin; this nonspecific manner is advantageous for lignin degradation because lignin is such a heterogeneous polymer.
Lignin and Mn peroxidases are two families of isozymes produced by P. chrysosporium under nutrient nitrogen or carbon limitation; three major Mn peroxidase isozymes have been identified: H3 (pI = 4.9), H4 (pI = 4.5), and H5 (pI = 4.2). These enzymes are glycosylated haemoproteins whose average molecular mass is 40 kDa.
Lignin degradation by P. chrysosporium involves various extracellular oxidative enzymes, including lignin peroxidase, manganese peroxidase, and a peroxide-generating enzyme, glyoxal oxidase; laccases also may be produced by this fungus, but these conclusions have been controversial. Four sequences related to laccases and ferroxidases have been identified in the P. chrysosporium database; one gene, designated mco1, has a typical eukaryotic secretion signal and is transcribed in defined media and in colonized wood.
The importance of extracellular H₂O₂ in lignin degradation has been linked to a new H₂O₂-producing activity of P. chrysosporium that involves extracellular oxidases (glyoxal oxidase) able to use simple aldehyde, alpha-hydroxycarbonyl, or alpha-dicarbonyl compounds as substrates; the activity is expressed during secondary metabolism, when the ligninases are also expressed. Two of the oxidase substrates, glyoxal and methylglyoxal, were identified as secondary metabolites in the culture fluid.
The model white rot fungus P. chrysosporium has the extraordinary ability to degrade and mineralize (to CO₂) lignin, the earth's most abundant aromatic polymer, and a wide range of toxic chemical pollutants; lignin biodegradation occurs under nutrient-limited conditions when the fungus enters secondary metabolism. Of the nearly 150 P450 monooxygenase genes identified in the P. chrysosporium genome, 108 have been assembled full-length; this is the highest number of P450s identified in any fungus, which appears to be one of the major underlying factors for its extraordinary catalytic potential. In addition, P. chrysosporium performs lignin degradation using various extracellular enzymes related to H₂O₂ production and intracellular enzymes, including cytochrome P450 monooxygenase.
Veratryl alcohol (3,4-dimethoxybenzyl alcohol) is a secondary metabolite found in ligninolytic cultures of Phanerochaete chrysosporium; it is synthesized de novo by way of phenylalanine, 3,4-dimethoxycinnamyl alcohol, and veratryl glycerol, and its onset of accumulation appears simultaneously with the activation of ligninolytic activity. Veratryl alcohol acts as a stabilizer of lignin peroxidase activity rather than as an inducer of lignin peroxidase synthesis.
The 30-million base-pair genome of Phanerochaete chrysosporium strain RP78 has been sequenced using a whole-genome shotgun approach. The P. chrysosporium genome reveals an impressive array of genes encoding secreted oxidases, peroxidases, and hydrolytic enzymes that cooperate in wood decay; analysis of the genome data has enhanced understanding of lignocellulose degradation, a pivotal process in the global carbon cycle. It is the first basidiomycete whose genome has been completely sequenced.
P. chrysosporium is the model white rot fungus because of its specialized ability to degrade the abundant aromatic polymer lignin, while leaving the white cellulose nearly untouched; it releases extracellular enzymes to break up the complex three-dimensional structure of lignin into components that can be utilized by its metabolism. The extracellular enzymes are non-specific oxidizing agents (hydrogen peroxide, hydroxyl radicals) used to cleave the lignin bonds.
Only white rot fungi are known to possess the ability to completely degrade lignin; the working hypothesis is that initial depolymerization of the lignin by extracellular peroxidases releases chemical compounds that are internalized and further degraded by diverse intracellular enzymes, including P450 monooxygenases. Several studies have shown that this fungus can degrade and mineralize a broad spectrum of aromatic, alicyclic, and aliphatic chemical pollutants under both nutrient-limited (ligninolytic) and nutrient-sufficient (non-ligninolytic) conditions.
The ligninolytic system is activated during secondary metabolism in response to nutrient limitation; during secondary metabolism, P. chrysosporium secretes extracellular peroxidases including MnP and LiP, and extracellular oxidases that produce H₂O₂ for the catalytic activity of the peroxidases. Not only are the lignin and Mn peroxidases differentially regulated, but differential regulation also occurs within the Mn peroxidase isozyme family, with the isozyme profile and the time at which each isozyme appears in secondary metabolism differing in both nitrogen- and carbon-limited cultures.
P. chrysosporium has been shown to degrade a variety of persistent environmental pollutants; many of the enzymes responsible for pollutant degradation are extracellular, allowing the fungus to degrade toxic or insoluble chemicals more efficiently than other microorganisms; it has a range of oxidative and reductive mechanisms and uses highly reactive, nonspecific redox mediators which increase the number of chemicals that can be effectively degraded.
Some of the lignin-degrading enzymes of P. chrysosporium also degrade toxic wastes such as PCBs and PCPs — this is because those substances have chemical bonds very similar to those found in lignin.
Phanerochaete chrysosporium, Pleurotus ostreatus, and Bjerkandera adusta are most commonly used for the degradation of PAHs due to their production of ligninolytic enzymes such as lignin peroxidase, manganese peroxidase, and laccase.
In laboratory studies, the removal of benzo(a)pyrene by free cells of P. chrysosporium strains ATCC 24725, ATCC 32639, and ATCC 34541 was observed in a nitrogen-limited incubation medium; investigations also examined removal of naphthalene, fluoranthene, and benzo(a)pyrene by immobilized white-rot fungus using a mixed gel biocarrier composed of alginate and powdered activated carbon; PAHs were removed at an increased rate during the stationary growth phase, and strain ATCC 24725 exhibited the best PAH removal efficiency.
Several ligninolytic culture collection strains, including P. chrysosporium BKM-F-1767, were tested in parallel PAH biodegradation assays; all tested strains significantly removed anthracene, and nine of the strains significantly removed benzo(a)pyrene beyond the limited losses observed in sterile and poisoned controls.
The ability of P. chrysosporium (INA-12) to degrade polynuclear aromatic hydrocarbons (PAH) was investigated; under static, non-nitrogen-limiting conditions it mineralized both phenanthrene and benzo[a]pyrene, but total mineralization was limited to 1.8%–3% for phenanthrene and benzo[a]pyrene respectively. This indicates that while significant biosorption and partial degradation occur, complete mineralization rates can be low under certain conditions, and results vary substantially depending on strain, culture conditions, and compound.
Evidence strength: Evidence is preclinical (laboratory/bench-scale experiments and bioreactor studies), primarily in vitro or at the mesocosm scale. No human clinical trials exist for this application.
Because of their unique ability to break down lignin and aromatic compounds, white rot fungi, especially Phanerochaete chrysosporium, are used in the treatment of lignocellulosic biomasses, industrial effluents, and decontamination; P. chrysosporium is by far the most popular WRF owing to its many applications.
In studies examining multiple dye classes, results were conclusive for five dyes investigated, namely Orange II, Red 8BLP, Direct black 80, Direct yellow 11, and Basic brown 1; by the end of the seventh day of culture, all solutions containing the dyes appeared almost completely decolorized.
In continuous treatment experiments, colored wastewater from a textile dyeing industry was treated using P. chrysosporium in a rotating biological contactor (RBC) reactor; dilution of the raw wastewater with media containing glucose at varying concentrations was studied, and a maximum decolorization efficiency of 83% was obtained with 10 g/L glucose concentration.
Evidence strength: Preclinical (in vitro, bioreactor, and bench-scale). No human health or clinical implications apply directly to these findings.
White-rot fungi are capable of degrading xenobiotic compounds such as polycyclic aromatic hydrocarbons or synthetic dyes; in one study, the transformation of three anti-inflammatory drugs — diclofenac, ibuprofen, and naproxen — was carried out by pellets of Phanerochaete chrysosporium in fed-batch bioreactors operating under continuous air supply or periodic pulsation of oxygen. The performance of the fungal reactors was steady over a 30-day treatment period; complete elimination of diclofenac was achieved in both aerated and oxygenated reactors, with a fast oxidation rate in the presence of oxygen (77% after 2 hours), reaching total removal after 23 hours; ibuprofen was completely oxidized under both air and oxygen supply.
White rot fungi and their ligninolytic enzymes have been widely applied in the removal of polycyclic aromatic hydrocarbons, pharmaceutically active compounds (PhACs), endocrine disruptor compounds (EDCs), pesticides, synthetic dyes, and other environmental pollutants.
Evidence strength: Preclinical (bioreactor and laboratory scale). These findings concern environmental remediation, not human therapeutic applications.
A polyvinyl alcohol (PVA)-immobilized P. chrysosporium biosorbent was applied to the bioremediation of composite-polluted wastewater containing both cadmium and 2,4-dichlorophenol (2,4-DCP); the optimum removal efficiency achieved was 78% for Cd(II) and 95.4% for 2,4-DCP at initial concentrations of 20 mg/L Cd(II) and 40 mg/L 2,4-DCP.
Evidence strength: Preclinical. These are materials science and environmental engineering experiments only.
Research has highlighted a novel role of P. chrysosporium as a source of antioxidants; extracts of P. chrysosporium possess remarkable antioxidant activity, expressing a dose-dependent total antioxidant activity and accompanied with high reactive oxygen radical (O₂⁻, OH, and H₂O₂) scavenging capacity.
Evidence strength: Preclinical, in vitro only. No clinical trials have examined antioxidant benefit in humans from consuming P. chrysosporium preparations.
One study evaluated the algicidal efficiency and genotoxic effects of co-culturing Microcystis aeruginosa with Phanerochaete chrysosporium for 48 hours; the results showed that the activity of algal dehydrogenase, superoxide dismutase, and peroxidase were all decreased and malondialdehyde content increased, while Fourier transform infrared spectroscopy and scanning electron microscopy showed significant changes in algal cell structure.
Evidence strength: Preclinical, laboratory conditions only.
It should be explicitly noted that Phanerochaete chrysosporium is not currently used as a human dietary supplement or therapeutic agent and is not approved by any regulatory authority for human internal use. All research associations below arise from its environmental and biotechnological properties, with indirect relevance to human health through environmental remediation.
Because Phanerochaete chrysosporium is not an established dietary supplement, there are no standard human dosage recommendations. However, specific quantities and conditions have been reported in laboratory and toxicological studies:
The first in vitro study examining cytotoxicity, genotoxicity, and oxidative damage of P. chrysosporium on human peripheral blood mononuclear cells (hPBMCs) concluded that consumption of P. chrysosporium can be safe for humans, but that it also has exposure-period and dose-dependent effects on inducing oxidative damage and toxicity on hPBMCs.
At concentrations of 5–75 µg/mL, P. chrysosporium extracts significantly increased antioxidant capacity and these doses did not cause any significant alterations to cytotoxicity; elevated doses of 5–250 µg/mL did not cause an increase in genotoxicity. However, at 250 and 500 µg/mL doses, statistically significant increases in total oxidant status (TOS), LDH release, chromosome aberration frequency, and micronucleus formation were observed, while TAC levels were decreased. These findings indicate a dose-dependent toxicity threshold in vitro.
Agaricomycetes, the class to which P. chrysosporium belongs, also includes pathogens when they target living organisms. However, P. chrysosporium itself is not classified as a human pathogen in standard mycological references. As a basidiomycete that produces airborne spores, it may theoretically present inhalation risks in occupational settings involving large-scale cultivation, though this has not been characterized in the peer-reviewed clinical literature.
Phanerochaete chrysosporium is not listed or approved by the U.S. Food and Drug Administration (FDA), the European Food Safety Authority (EFSA), or any other major regulatory body as a dietary supplement ingredient, food additive, or medicinal product for human consumption. It does not appear in the NIH Office of Dietary Supplements databases, WHO monographs, ESCOP monographs, German Commission E monographs, or European Pharmacopoeia as a recognized supplement or herbal medicine.
Research has found that strains including Phanerochaete sp. can convert anthracene to anthraquinone, which was found to be a dead-end metabolite in high yields, highlighting that metabolic transformation of xenobiotics can produce persistent by-products whose safety profiles require further investigation.
P. chrysosporium is a cadmium (Cd) and sulfamethazine (SMT) hyper-accumulation species; research was performed to investigate the single and combined effects of Cd-SMT, including toxicity, resistance, as well as accumulation and biotransformation by P. chrysosporium. The results revealed that Cd-SMT co-contamination caused increasing active oxygen accumulation, and the number of antioxidant enzymes and non-enzymatic antioxidants were higher under co-pollution stress than under single pollutant stress. This suggests that preparations of the fungus cultivated in contaminated environments could accumulate heavy metals or recalcitrant compounds, posing potential risks in any hypothetical human exposure scenario.
Phanerochaete chrysosporium occupies a unique position in applied biology as the most extensively studied white rot fungus, primarily for its extraordinary capacity to degrade lignin and a broad spectrum of environmental pollutants. It is the most extensively characterized white rot fungus and has been the subject of extensive investigation and many biodegradation studies. However, as a dietary supplement or human health agent, all evidence remains at the preclinical stage — comprising in vitro cell-culture experiments, laboratory bench studies, and bioreactor research. There are no published randomized controlled trials, systematic reviews, or meta-analyses evaluating P. chrysosporium for any human health outcome. No established dosages, therapeutic indications, or safety profiles for human consumption have been validated by regulatory bodies or clinical research.
Health conditions that Phanerochaete chrysosporium may help support.
Body systems that Phanerochaete chrysosporium may help support.
Go back